Patrick Schöffski
Impact in
- Gastroenterology top 0.05%
- Gastrointestinal Tumor Research and Treatment
- Oncology top 0.1%
- Colorectal Cancer Treatments and Studies
- Vascular Tumors and Angiosarcomas
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Sarcoma Diagnosis and Treatment 126
- Gastric Cancer Management and Outcomes 49
- Renal cell carcinoma treatment 43
- Oncology 157
- Colorectal Cancer Treatments and Studies 35
- Cancer Treatment and Pharmacology 31
- Vascular Tumors and Angiosarcomas 30
- Co-authors
- Jean‐Yves Blay (85 shared papers)Maria Dêbiec‐Rychter (81 shared papers)Agnieszka Woźniak (105 shared papers)Raf Sciot (95 shared papers)Herlinde Dumez (63 shared papers)Jaap Verweij (27 shared papers)Hans Gelderblom (49 shared papers)Pascal Wolter (40 shared papers)
- Journals
- Journal of Clinical Oncology (126 papers)Annals of Oncology (49 papers)European Journal of Cancer (47 papers)Clinical Cancer Research (24 papers)Cancer Research (20 papers)
- Partner nations
- BelgiumUnited StatesGermany
In The Last Decade
Patrick Schöffski
502 papers receiving 20.0k citations
Patrick Schöffski's Hit Papers
Peers
Comparison fields: 5 of 151
- Gastroenterology 2.7k
- Oncology 7.7k
- Pulmonary and Respiratory Medicine 7.8k
- Cancer Research 1.8k
- Pathology and Forensic Medicine 1.5k
Countries citing papers authored by Patrick Schöffski
This map shows the geographic impact of Patrick Schöffski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Schöffski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Schöffski more than expected).
Fields of papers citing papers by Patrick Schöffski
This network shows the impact of papers produced by Patrick Schöffski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Schöffski. The network helps show where Patrick Schöffski may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick Schöffski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 517 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cabozantinib in Progressive Medullary Thyroid Cancer Hit paper breakdown → | 2013 | 909 |
| 2 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Hit paper breakdown → | 2014 | 838 |
| 3 | Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer Hit paper breakdown → | 2004 | 647 |
| 4 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2016 | 561 |
| 5 | Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) Hit paper breakdown → | 2009 | 553 |
| 6 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Hit paper breakdown → | 2009 | 475 |
| 7 | 2001 | 446 | |
| 8 | Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Hit paper breakdown → | 2017 | 442 |
| 9 | 2004 | 433 | |
| 10 | 2002 | 368 | |
| 11 | 2002 | 281 | |
| 12 | Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2020 | 265 |
| 13 | 2009 | 248 | |
| 14 | 2006 | 240 | |
| 15 | 2009 | 194 | |
| 16 | 2005 | 194 | |
| 17 | 2010 | 185 | |
| 18 | 2011 | 182 | |
| 19 | 2017 | 181 | |
| 20 | 2012 | 173 |
About Patrick Schöffski
Patrick Schöffski is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Gastroenterology, Molecular Biology and Surgery, having authored 517 papers that have together received 20.5k indexed citations. Recurring topics across this work include Gastrointestinal Tumor Research and Treatment (135 papers), Sarcoma Diagnosis and Treatment (126 papers), Gastric Cancer Management and Outcomes (49 papers), Renal cell carcinoma treatment (43 papers), Colorectal Cancer Treatments and Studies (35 papers), Cancer Genomics and Diagnostics (31 papers), Cancer Treatment and Pharmacology (31 papers) and Vascular Tumors and Angiosarcomas (30 papers). The work is most often cited by research in Gastroenterology (2.7k citations), Oncology (7.7k citations), Pulmonary and Respiratory Medicine (7.8k citations), Cancer Research (1.8k citations) and Pathology and Forensic Medicine (1.5k citations). Patrick Schöffski has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Jean‐Yves Blay, Maria Dêbiec‐Rychter, Agnieszka Woźniak, Raf Sciot, Herlinde Dumez, Jaap Verweij, Hans Gelderblom, Pascal Wolter, Sandrine Marréaud and Axel Le Cesne. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Clinical Cancer Research and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.